Antiva Biosciences Stock

www.antivabio.com/HealthcareFounded: 2012

Antiva Biosciences, founded in 2012, is a biopharmaceutical company most well known for their development of small molecule antivirals that improve health outcomes for patients suffering from diseases caused by HPV and other viruses. The company's antivirals are based on a medicinal chemistry platform that focuses on the development and commercialization of direct-acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses. Antiva Biosciences is headquartered in South San Francisco, California.

Register for Details

For more details on financing and valuation for Antiva Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Antiva Biosciences.

Register Today

Team

Management Team

Kristine M. Ball
President & CEO
Oranee Daniels, MD
Chief Medical Officer
Raju Gadiraju, PhD
Senior Vice President of Pharmaceutical Development and Manufacturing
Sarah Walter, PhD
Senior Vice President of Nonclinical Development & Global Health Strategy
Michael Cordingley, PhD
Senior Virology Adviser

Board Members

Wende S. Hutton
Canaan Partners
Clifford M. Samuel
PCMS1 Consulting
Jenny Yip
Adjuvant Capital
Florencia Segal
MPM-BioImpact Capital
Brian Goodman
MPM-BioImpact Capital

Other companies like Antiva Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B